ARQT vs. CAMT

In the year-to-date period, ARQT achieves a -5.96% return, which is significantly lower than CAMT's 9.20% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and Camtek Ltd (CAMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ARQT Sharpe Ratio is 1.25, which is higher than the CAMT Sharpe Ratio of 0.21. The chart below compares the historical Sharpe Ratios of ARQT and CAMT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

ARQT has not paid dividends to shareholders, while CAMT's dividend yield for the trailing twelve months is around 1.51%.

The maximum ARQT drawdown since its inception was -95.02%, roughly equal to the maximum CAMT drawdown of -97.74%. Use the drawdown chart below to compare losses from any high point for ARQT and CAMT. For additional features, visit the drawdowns tool.

The current volatility for Arcutis Biotherapeutics, Inc. (ARQT) is 18.93%, while Camtek Ltd (CAMT) has a volatility of 23.18%. This indicates that ARQT experiences smaller price fluctuations and is considered to be less risky than CAMT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Arcutis Biotherapeutics, Inc. and Camtek Ltd. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.